Revenue Update on Edwards Lifesciences Corp(NYSE:EW)

Edwards Lifesciences Corp(NYSE:EW) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Jul 26, 2016. Company reported revenue of $759.30M. Analysts estimated a revenue of $724.51M. Earnings per share were $0.76. Analysts had estimated an EPS of $0.70.

In a different note, Guggenheim Securities said it Initiates Coverage on Edwards Lifesciences Corp, according to a research note issued on Jun 9, 2016. The shares have been rated ‘Neutral’ by the firm.

Edwards Lifesciences Corp (EW) made into the market gainers list on Fridays trading session with the shares advancing 1.35% or 1.53 points. Due to strong positive momentum, the stock ended at $114.52, which is also near the day’s high of $114.79. The stock began the session at $113 and the volume stood at 13,85,289 shares. The 52-week high of the shares is $117.46 and the 52 week low is $62.53. The company has a current market capitalization of $24,251 M and it has 21,17,62,740 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jul 7, 2016, Huimin Wang (CVP, Japan & Intercontinental) sold 13,650 shares at $98.44 per share price.Also, On Jul 5, 2016, Larry L Wood (CVP, THV Replacement) sold 13,257 shares at $99.13 per share price.On Jun 9, 2016, Michael A Mussallem (Chairman & CEO) sold 49,100 shares at $102.25 per share price, according to the Form-4 filing with the securities and exchange commission.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Edwards Lifesciences Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Edwards Lifesciences Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.